Wells Fargo Downgrades Viridian Therapeutics(VRDN.US) to Hold Rating, Cuts Target Price to $27

Futu NewsDec 21 02:31 · Ratings

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

BenzingaDec 19 22:07

Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target

BenzingaDec 19 20:34 · Ratings

Buy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED Treatment

TipRanksDec 18 13:45 · Ratings

RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $47

Futu NewsDec 18 02:31 · Ratings

Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views

BenzingaDec 18 02:00